Human Oncology & Pathogenesis Program
The Barry Taylor Lab
The focus of our lab is to identify the somatic genomic abnormalities that mediate cancer development or progression or influence how tumors respond to therapy. We are particularly focused on discovering abnormalities that lead to distinct clinical phenotypes and reveal mechanisms of molecular pathogenesis.
Al-Ahmadie H, Iyer G, Hohl M, Asthana S, Schultz N, Hanrahan AJ, Scott SN, Brannon AR, McDermott GC, Pirun M, Ostrovnaya I, Kim P, Socci ND, Viale A, Schwartz GK, Reuter V, Bochner B, Rosenberg JE, Bajorin DF, Berger MF, Petrini JH**, Solit DB**, Taylor BS**. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlie outlier response to cancer therapy. Cancer Discov. 2014; 4(9); 1014-1021
Johnson BE, Mazor T, Hong C, Barnes M, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Aihara K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungal AJ, Jones SJM, Hirst M, Marra MA, Mukasa A, Saito N, Aburatani H, Berger MS, Chang SM, Taylor BS**, Costello JF**. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science, 2014; 343(6167): 189-93.
Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M. Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, Bajorin DF, Berger MF, Taylor BS**, Solit DB**. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012; 338(6104): 221.
Barretina J*, Taylor BS*, Ramos AH, Lagos-Quintana M, Banerji S, DeCarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel C, Getz G, Antipin Y, Beroukhim R, Major JE, Hatton C, Nicoletti R, Hanna M, Sharpe T, Fennell T, Cibulskis K, Onofrio RC, Saito T, Shukla NN, Lau C, Nelander S, Silver S, Sougnez C, Viale A, Winckler W, Maki RG, Garraway LA, Lash A, Greulich H, Root D, Sellers WR, Schwartz GK, Antonescu CR, Lander ES, Varmus HE, Ladanyi M, Sander C, Meyerson M, and Singer S. Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy. Nature Genetics. 2010; 42(8): 715-21.
Taylor BS*, Schultz N*, Hieronymus H*, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1): 11-22.
Barry S. Taylor, PhD
Associate Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology
- Researcher Barry Taylor focuses on defining the somatic abnormalities that mediate the genesis, progression, and response to therapy of human cancers.
- PhD, Weill Cornell Medical College
- BS, Computer Science and Film
- Predoctoral Graduate Student, UCSF
- American Cancer Society Research Scholar Award
- Josie Robertson Investigator, Memorial Sloan Kettering Cancer Center (2014)
- Distinguished Scientist Award, Sontag Foundation (2013)
- Young Investigator Award, Prostate Cancer Foundation (2011)
- Young Investigator Award, Connective Tissue Oncology Society (2009)
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Barry S. Taylor discloses the following relationships and financial interests:
Provision of Services
Provision of Services
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.